Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

NCT03055013 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03055013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03055013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 28, 2017
Completion date
June 9, 2031
Enrollment
819 (actual)
Sites
413

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, sarcomatoid renal cell carcinoma, stage ii renal cell cancer ajcc v7, stage iii renal cell cancer ajcc v7, unclassified renal cell carcinoma